menu
    • menu
    [{"orgOrder":0,"company":"Stanford University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Talazoparib Tosylate","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Talazoparib Tosylate

    Menu

    Talazoparib Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stanford University

                            Country arrow
                            PackExpo
                            Not Confirmed

                            Stanford University

                            Country arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Talazoparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

                            Details : Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 16, 2021

                            Lead Product(s) : Talazoparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Melinda Telli

                            Country arrow
                            PackExpo
                            Not Confirmed

                            Melinda Telli

                            Country arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Talazoparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : BioMarin Pharmaceutical | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

                            Details : Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 27, 2015

                            Lead Product(s) : Talazoparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : BioMarin Pharmaceutical | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth